FRAMINGHAM, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--SCIEX, a global leader in life science analytical technologies, and Intabio, a developer of innovative instrumentation systems for biotherapeutic precision analysis and quality assessment, announced a collaboration to couple Intabio's Blaze™ system with SCIEX high resolution accurate mass (HRAM) systems. This collaboration is geared to accelerate and transform biotherapeutic development and biomanufacturing.
The integration between Blaze and SCIEX HRAM systems provides imaged capillary isoelectric focusing with mass spectrometry (iCIEF-MS) in order to simultaneously characterize and identify intact protein charge variants. The successful integration of iCIEF-MS workflows will streamline current laborious and time-consuming approaches in the biopharma environment to identify, monitor and characterize critical quality attributes in intact protein samples for the development and manufacture of next-gen therapeutics.
“By coupling iCIEF separations directly to leading high resolution MS systems, the Blaze system eliminates a serious laboratory bottleneck for drug developers,” said Lena Wu, Ph.D., Intabio CEO and co-founder. “Blaze integration with SCIEX flagship MS platforms will enable biopharma to accelerate critical decisions and ultimately reduce development timelines.”
The commercial release of the Blaze™ system is scheduled for Q4 of 2020 and the integrated iCIEF-MS workflow will be available on SCIEX TripleTOF® 6600+ Systems.
“This work demonstrates our continued commitment to collaborate with key innovators to develop practical solutions for our biopharmaceutical customers,” said Mani Krishnan, Vice President of Global Biopharma and Capillary Electrophoresis at SCIEX. “Providing analytical workflows around iCIEF-MS will assist in solving some of the key challenges faced by the industry.”
About SCIEX
SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. We have led the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed groundbreaking technologies and solutions that influence life-changing research and outcomes.
Today, as part of the Danaher family of global life science and technology innovators, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers are able to quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer.
That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.
For more information, visit sciex.com.
Let’s connect: Twitter, LinkedIn, Facebook, and Instagram.
Advances in human wellness depend on the power of precise science.
The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to https://sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.
Trademarks and/or registered trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries.
© 2020 DH Tech. Dev. Pte. Ltd. RUO-MKT-12-11287-A
About Intabio
Intabio, Inc. is a Silicon Valley-based company developing analytical solutions to transform biotherapeutic development and manufacturing with products that provide early product quality characterization and profound efficiency gains across all stages of biopharmaceutical development and manufacturing. Intabio's first product, the Blaze system, is a microchip-based instrument system that will provide rapid detection and identification of subtle protein modifications - modifications that can undermine the stability and efficacy of biotherapeutic drugs such as monoclonal antibodies and recombinant proteins.
For more information, visit www.intabio.com.
Connect with Intabio: LinkedIn, Twitter, and YouTube.
